[Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
The aim of study was the evaluation of tissue plasminogen activator (t-PA) and its inhibitor (PAI-1) in the II type diabetes on the base of the common fibrinolytic system tests as euglobulin lysis time (ELT) and the concentration of fibrin/fibrinogen products (FDP). The studies were performed in 21 outpatients suffering of II type diabetes aged 38-65 (median 56.0) years treated with diet and sulphonylcarbamide derivates. The control group contained 18 healthy persons aged 33-65 (median 42.0) years. In the blood the following determinations were performed: antigen of t-PA and PAI-1, ELT and FDP. In the blood of patients with II type diabetes increased. t-PA Ag and PAI-1 Ag concentrations were observed.
Rość
D
D
Katedry i Zakładu Patofizjologii, Bydgoszczy.
Drewniak
W
W
Kotschy
M
M
Graczykowska-Koczorowska
A
A
Raukuć
D
D
D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000502:physiology*; D010959:Tissue Plasminogen Activator / Q000502:physiology*
D015849:Plasminogen Inactivators; D010959:Tissue Plasminogen Activator